Company intelligence / Profile preview

Wellstat Ophthalmics

Gaithersburg / Rockville, Maryland, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Wellstat Ophthalmics is a private biotechnology company focused on developing recombinant protein therapeutics for ophthalmic diseases. Its lead program, AVT-101, is in the discovery stage targeting macular dystrophy. Another early-stage program involves anti-angiogenic ocular gene therapies aimed at diabetic retinopathy. There are no reported clinical results or late-stage assets as of early 2025.

Therapeutic areas: Ophthalmology
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Wellstat Ophthalmics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellstat Ophthalmics.

Explore the full profile